November 17, 2021 — Taking daily low-dose aspirin for seven years did not affect the risk of dementia or mental decline ...
Pharmaceuticals
This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.
November 17, 2021 — Canagliflozin, a medication used to treat type 2 diabetes, was found to greatly improve symptoms and ...
November 15, 2021 — Novartis announced results from a pooled post-hoc analysis of Phase III ORION-9, -10 and -11 trials ...
November 9, 2021 — Utilizing a magnetically-controlled capsule endoscopy system, the double-blind, randomized OPT-PEACE ...
November 5, 2021 — In the worldwide effort to battle COVID-19 (SARS-CoV-2), researchers have often turned to medications ...
November 5, 2021 — The U.S. Food and Drug Administration (FDA) authorized the emergency use of the Pfizer-BioNTech COVID ...
There has been debate in recent years over balancing the risks vs. benefits of aspirin for the prevention of heart ...
October 7, 2021 – The U.S. Food and Drug Administration (FDA) recently granted the breakthrough therapy designation for ...
October 1, 2021 — A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in ...
October 4, 2021 — One month of dual antiplatelet therapy (DAPT) following stent implantation in high bleeding risk ...
September 28, 2021 — A research team at the University of Arkansas for Medical Sciences (UAMS) has identified a ...
September 8, 2021 — Continuous heart rhythm monitoring – with anticoagulation if atrial fibrillation is detected – does ...
September 1, 2021 — The STOPDAPT-2 ACS trial does not support the use of one month of dual antiplatelet therapy (DAPT) ...
September 1, 2021 – The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart ...